Biomarin Pharmaceutical Inc
NASDAQ: BMRN
$66.15
+$0.11 (+0.2%)
Closing Price on November 6, 2024
BMRN Articles
Friday's top analyst upgrades, downgrades and initiations include BioMarin Pharmaceuticals, BP, Micron Technology, Vonage, Finisar, Consolidated Edison and Red Hat.
Published:
BioMarin Pharmaceutical has three key drivers helping out its shares on Thursday: drug news, analyst support, record high Nasdaq.
Published:
A recent research piece from the analysts at Jefferies presents the firm's four top growth stock calls for this holiday-shortened trading week.
Published:
A new research note from SunTrust Robinson Humphrey mentions four stocks that they think could possibly get swept up in the biotech M&A excitement.
Published:
In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the right time to add biotech stocks.
Published:
In a new report from RBC, while they think the selling and profit taking in biotechs could go on, they also hold fast that industry fundamentals are still very positive.
Published:
Wells Fargo released a report Wednesday that considers the future of major biotech companies in relation to the weak euro.
Published:
Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics acquisition.
Published:
These four companies are not only delivering the goods when it comes to earnings and growth prospects, but leading their respective industries in innovation.
Published:
Sarepta Therapeutics received a favorable rating from Merrill Lynch, and as a result the stock soared in Tuesday's trading session.
Published:
Last Updated:
BioMarin Pharmaceutical received a favorable analyst call from Merrill Lynch in Monday.
Published:
Last Updated:
Here are the five biotech stocks that are loved the most by portfolio managers, according to Cowen analysts.
Published:
Thursday's top analyst upgrades, downgrades and initiations seen from Wall Street research calls includes Alcatel-Lucent, ADM, Bank of America, Chesapeake Energy, Google, J.P. Morgan and MGM.
Published:
ThinkstockLooking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech index was up over 45% for 2014, and Wells Fargo expects that the biotech...
Published:
Last Updated:
Out of 28 biotech stocks with market capitalization rates north of $300 million that were up 100% or more in 2014, seven of them were up 300% or more.
Published: